The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.

Acta chirurgica Iugoslavica

Volumn 55, Issue 4, 2008, Pages 11-16

  Popov, I ^a   Milicevic M ^a   Radosevic Jelic L ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX;

ADENOCARCINOMA; ARTICLE; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; METASTASIS; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE;

EID: 63249109792     PISSN: 0354950X     EISSN: None     Source Type: Journal    
DOI: 10.2298/ACI0804011P     Document Type: Article

References (0)